#### Published

- <strong>Dingbang. Xie</strong>, Hui. Yan*, Yunteng. Xu, Yimin. Zhang, Wanping. Cai, and Xin. Lan (2023). Pyruvate dehydrogenase kinase 1–dependent metabolic reprogramming: A promising target for postmenopausal osteoporosis treatment. <strong>Biomedicine & Pharmacotherapy</strong>. [[Paper]](https://linkinghub.elsevier.com/retrieve/pii/S0753332223001993)

- <strong>Dingbang. Xie</strong>, Hui. Yan*, Yunteng. Xu, Wanping. Cai, Zhuo. Junkuan，Zaishi. Zhu, Haifeng. Zhang and Yimin. Zhang  (2023). Icariin promotes osteogenic differentiation by upregulating alpha-enolase expression. <strong>Biochemistry and Biophysics Reports. [[Paper]](https://linkinghub.elsevier.com/retrieve/pii/S2405580823000523) 

- <strong>Dingbang. Xie</strong>, Yimin. Zhang, Hui. Yan*, Xin. Lan，Wanping. Cai，Yangrong.Lin，Jingdi. Li and Yihang. Zou (2024). Identification of key ferrotoposis-related therapeutic targets in icariin efficacy for postmenopausal osteoporosis treatment. <strong>Pharmacological Research - Modern Chinese Medicine</strong>. [[Paper]](https://linkinghub.elsevier.com/retrieve/pii/S2667142524000708)

- Yunteng. Xu*，Dezun. Ma*，Hui. Yan，Jingdi. Li，<strong>Dingbang. Xie</strong>, Yaoting. Zou, and Jiapo. Zou (2025). miR-376c-3p mediates icariin's anti-osteoclastogenic effect by targeting Mmp3. <strong>Journal of Orthopaedic Surgery and Research</strong>.[[Paper]](https://pubmed.ncbi.nlm.nih.gov/41484919/)